Ann Meulemans and Tomas Van Dyck will serve as co-CEOs as 2 Bridge invests in long-term strategic and profitable growth
Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. In the past years, Tomas held Finance Director and CFO roles in various Belgian companies focusing on business partnership, process excellence, and strategic finance.
In his new role as co-CEO, Tomas will take leadership over the business organization and core corporate functions to achieve the company’s operational and financial excellence ambition. Ann will continue using her healthcare knowledge and vast experience working with investors, biotechs, startups, and pharma to drive 2 Bridge’s growth plan at scale and expand the company’s portfolio and geographic coverage.
Ann and Tomas share the same vision for 2 Bridge to bring the business to the next level, where 2 Bridge plays an essential role in thriving the life science ecosystem in Belgium, in Europe. Co-leading the organization will allow them to complement each other’s skill sets and enable the organization to improve its operational efficiency, strengthen its know-how, and forge more robust networks of business partners, which can benefit all parties.
About 2 Bridge
2 Bridge is the go-to company for those venturing into life sciences, including investors, startups, biotechs, and pharma. The science of Healthcare Product Development is our core area of expertise, and building companies according to a client-tailored design is our second nature.
Your Partner in Quality, Safety, and Compliance
The life sciences sector requires specialized knowledge and reliable guidance. Thanks to our extensive expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.
Related services
Related Articles
17 Nov 2025
A deep dive into the complexity of Advanced Therapy Medicinal Products
Each ATMP is unique in its characteristics for one given indication.
18 Aug 2025
Welcome Thomas Turner
We’re delighted to welcome Thomas Turner, PhD to 2 Bridge as a Consultant – Translational Science.
25 Jun 2025
Welcome, Pieter Vaneynde
Pieter Vaneynde Associate Consultant, Quality
20 May 2025
Why Every Compound Development Team Needs a Project Leader
What to expect in this blog 1. The Visionary Behind Science Understanding the Role of Project Leaders 2. The Captain’s Mission Steering the Team towards Success 3. Navigating Rough Seas The Multi-tasks of the Project Leader 4. From Vision to Value Qualifications of a Drug Development Captain
14 May 2025
How Project Management Leaders Steer Tiger Teams in Drug Development
What to expect in this blog 1. The Maestro Behind the Scenes The Role of a Project Management Leader in a Tiger Team 2. Purpose Navigating the Complexity of Drug Development 3. Responsibilities Turning Strategy into Action 4. Skillset Communication and Collaboration 5. Conclusion The Compass of a Tiger Team
22 Apr 2025
Drug Development Is Not A Solo Mission
What to expect in this blog 1. Industrial pain and challenges Thriving but also challenging life science landscape 2. Why can’t you do drug development all alone Independent of the development stage your compound is in, it takes a ‘Tiger Team’ to rocket it to the next step 3. A dynamic and agile strategy to tackle the challenges In 2013, 2 Bridge is Born From NASA’s Tiger Team to drug development: How 2 Bridge aims for the moon in pharma innovation 4. Benefits of working with a Cross-Functional Tiger Team If you are a startup, you gain… If you are an investor, you benefit from…
18 Feb 2025
2 Bridge Receives Crédit d’Impôt Recherche (CIR) Accreditation
English Announcement 2 Bridge is pleased to announce that the French Ministry of Higher Education, Research, and Innovation has officially granted the company accreditation for the Crédit d’Impôt Recherche (CIR) for the years 2024, 2025, and 2026.